Immunogenicity of equine herpesvirus type 1 (EHV1) and equine rhinovirus type 1 (ERhV1) following inactivation by betapropiolactone (BPL) and ultraviolet (UV) light
- PMID: 6301141
- DOI: 10.1016/0378-1135(82)90047-5
Immunogenicity of equine herpesvirus type 1 (EHV1) and equine rhinovirus type 1 (ERhV1) following inactivation by betapropiolactone (BPL) and ultraviolet (UV) light
Abstract
Some kinetic data on the inactivation of equine herpesvirus type 1 (EHV1) and equine rhinovirus type 1 (ERhV1) by betapropiolactone (BPL) and ultraviolet (UV) irradiation are reported. 0.25% BPL at 37 degrees C for 1 h reduced the titre of EHV1 by greater than 10(3 . 4) and of ERhV1 by greater than 10(4 . 1) TCID50/ml. UV irradiation (334 microW/cm2) produced similar reductions in titre after 2 min. These data were used as a basis for inactivating EHV1 and ERhV1 by the combined action of BPL and UV irradiation. Viruses were exposed to 0.1% BPL for 1 h at 4 degrees C with constant stirring, followed by UV irradiation for 2 min, followed by incubation for 3 h at 37 degrees C. Inactivated EHV1 elicited secondary immune responses only in horses whereas ERhV1 produced primary immune responses in mice (including athymic nu/nu mice), rabbits and probably in horses.
Similar articles
-
Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus).Am J Vet Res. 1984 Oct;45(10):1947-52. Am J Vet Res. 1984. PMID: 6208822
-
Efficacy of an inactivated vaccine for equine herpesvirus type 1 in a novel hamster model.Intervirology. 2000;43(1):27-35. doi: 10.1159/000025020. Intervirology. 2000. PMID: 10773735
-
Immunokinetics of equine herpesvirus 1 in donkey mares: suppression of secondary cell-mediated response.Rev Sci Tech. 1992 Sep;11(3):901-8. doi: 10.20506/rst.11.3.636. Rev Sci Tech. 1992. PMID: 1335311
-
Towards a vaccine against equine herpesvirus 1.Aust Vet J. 1989 Dec;66(12):403-4. doi: 10.1111/j.1751-0813.1989.tb13559.x. Aust Vet J. 1989. PMID: 2559691 Review. No abstract available.
-
Vaccination against diseases associated with herpesvirus infections in animals: a review.IARC Sci Publ (1971). 1978;(24 Pt 2):965-80. IARC Sci Publ (1971). 1978. PMID: 221416 Review.
Cited by
-
Genetic restriction of cytolysis during equid herpesvirus 1 subtype 2 infection.Clin Exp Immunol. 1987 Nov;70(2):276-82. Clin Exp Immunol. 1987. PMID: 2827921 Free PMC article.
-
In situ vaccine application of inactivated CPMV nanoparticles for cancer immunotherapy.Mater Adv. 2021 Mar 7;2(5):1644-1656. doi: 10.1039/D0MA00752H. Epub 2021 Feb 3. Mater Adv. 2021. PMID: 34368764 Free PMC article.
-
Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses.J Biol Chem. 2011 Oct 21;286(42):36198-214. doi: 10.1074/jbc.M111.279232. Epub 2011 Aug 25. J Biol Chem. 2011. PMID: 21868382 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials